Immunotherapy and Chemotherapy Combination for Advanced Liver Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with advanced hepatocellular carcinoma (HCC) that cannot be surgically removed
- No prior cancer treatment for HCC
- Good overall health and liver function (Child-Pugh score A or B)
- Normal or near-normal blood cell counts, kidney function, and blood clotting ability
- Expected to live longer than 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two types of immunotherapy (atezolizumab with bevacizumab or durvalumab with tremelimumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. It aims to see if these treatments are safe and effective.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This trial combines an immunotherapy (Envafolimab), a targeted therapy (Suvemcitug), and a special chemotherapy infusion that goes directly into the liver (HAIC) to try to shrink or control advanced liver cancer that can't be removed by surgery. The goal is to help convert the tumor to a state where it might be operable, and to improve long-term outcomes.
This study looks at different first-line immunotherapy treatments for people with advanced liver cancer that cannot be treated with surgery or local therapies. It aims to understand how well these treatments work and how they affect the body's immune system.
Hear when a new Conversion Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.